Medicine
Bloxiverz 5 mg/5 mL injection
Bloxiverz 5 mg/5 mL injection is a prescription medicine containing Neostigmine methylsulfate for intravenous use, marketed by Exela Pharma Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store in carton until time of use.
Key facts
- Active ingredient (INN)
- Neostigmine methylsulfate
- Brand
- Bloxiverz
- Strength
- 5 mg/5 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 syringes of 5 mL
- Marketing authorisation holder
- Exela Pharma Sciences
- Manufacturer
- Exela Pharma Sciences
- Origin register
- US FDA, United States
- Storage
- Store in carton until time of use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 November 2023
- Identifiers
- RxCUI 311935, 311936, 1429282 +3DailyMed set ID d2f55643-2b0d-4ef9-a9d8-b7138b314372NDC 51754-1200Application NDA204078
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 syringe, plastic in 1 carton / 5 mL in 1 syringe, plastic | 51754-1200-3 | Exela Pharma Sciences | 31 December 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 May 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Neostigmine methylsulfate
Clinical summary
Neostigmine methylsulfate is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. It is available as injection for intravenous use. MedsAcross supplies Neostigmine methylsulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Neostigmine methylsulfateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Bloxiverz prescribing information (Exela Pharma Sciences) · U.S. National Library of Medicine, DailyMed
Need Bloxiverz 5 mg/5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.